Polomar Health Services (PMHS) Total Current Liabilities (2022 - 2026)
Polomar Health Services (PMHS) posted Total Current Liabilities of $1.8 million for Q1 2026, up 9.29% on a QoQ basis from $1.6 million in Q4 2025, and up 6.13% year-over-year from $1.7 million in Q1 2025.
Analysis
Polomar Health Services (PMHS) Total Current Liabilities (2022 - 2026) Analysis & Trends
Polomar Health Services has reported Total Current Liabilities for 5 years, with the latest figure at $1.8 million in Q1 2026.
- On a quarterly basis, Total Current Liabilities rose 6.13% year-over-year to $1.8 million in Q1 2026; TTM through Mar 2026 was $1.8 million, a 6.13% increase from a year earlier, with the FY2025 full-year figure at $1.6 million, up 20.53% from the prior year.
- Total Current Liabilities was $1.8 million for Q1 2026 at Polomar Health Services, up from $1.6 million in the prior quarter.
- The five-year high for Total Current Liabilities was $1.8 million in Q1 2026, with the low at $14027.0 in Q2 2023.
- Average Total Current Liabilities over 5 years is $789104.0, with a median of $953763.0 recorded in 2024.
- The sharpest annual moves came in 2024 and 2026: Total Current Liabilities jumped 6296.37% in 2024, then climbed 6.13% in 2026.
- Over 5 years, Total Current Liabilities stood at $74715.0 in 2022, then jumped by 37.13% to $102455.0 in 2023, then soared by 1205.72% to $1.3 million in 2024, then gained by 20.53% to $1.6 million in 2025, then increased by 9.29% to $1.8 million in 2026.
- The last three Total Current Liabilities figures came in at $1.8 million (Q1 2026), $1.6 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | 15.65 Bn |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | 6.35 Bn |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | 1.66 Bn |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | 883.19 Mn |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | 4.54 Bn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | 331.18 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 283.66 Mn |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | 263.21 Mn |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | 12.39 Mn |
| 10 | Polomar Health Services | 5.66 Mn | 5.48 Mn | 935,916.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 1.76 Mn |
| Dec 31, 2025 | 1.61 Mn |
| Sep 30, 2025 | 1.50 Mn |
| Jun 30, 2025 | 1.04 Mn |
| Mar 31, 2025 | 1.66 Mn |
| Dec 31, 2024 | 1.34 Mn |
| Sep 30, 2024 | 953,763.00 |
| Jun 30, 2024 | 102,973.00 |
| Mar 31, 2024 | 82,807.00 |
| Dec 31, 2023 | 102,455.00 |
| Sep 30, 2023 | 14,911.00 |
| Jun 30, 2023 | 14,027.00 |
| Dec 31, 2022 | 74,715.00 |